Stage-Wise IoT Solutions for Alzheimer's Disease: A Systematic Review of Detection, Monitoring, and Assistive Technologies
Abstract
The Internet of Things (IoT) has emerged as a transformative technology in managing Alzheimer's Disease (AD), offering novel solutions for early diagnosis, continuous patient monitoring, and assistive care. This review presents a comprehensive analysis of IoT-enabled systems tailored to AD care, focusing on wearable biosensors, cognitive monitoring tools, smart home automation, and Artificial Intelligence (AI)-driven analytics. A systematic literature survey was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify, screen, and synthesize 236 relevant studies primarily published between 2020 and 2025 across IEEE Xplore, PubMed, Scopus and Web of Science. The inclusion criteria targeted peer-reviewed articles that proposed or evaluated IoT-based solutions for AD detection, progression monitoring, or patient assistance. Key findings highlight the effectiveness of the IoT in detecting behavioral and cognitive changes, enhancing safety through real-time alerts, and improving patient autonomy. The review also explores integration challenges such as data privacy, system interoperability, and clinical adoption. The study reveals critical gaps in real-world deployment, clinical validation, and ethical integration of IoT-based systems for Alzheimer's care. This study aims to serve as a definitive reference for researchers, clinicians, and developers working at the intersection of the IoT and neurodegenerative healthcare.
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.